HIGHLIGHTS
- who: Cristina Di Giorgio and colleagues from the Department of Medicine and Surgery, University of Perugia, Perugia, Italy have published the paper: Repositioning Mifepristone as a Leukaemia InhibitoryFactor Receptor Antagonist for the Treatment ofPancreatic Adenocarcinoma, in the Journal: Cells 2022, 11, 3482. of /2022/
- what: The main reason for the dismal prognosis of PDAC is a late diagnosis, since u224890% of cancer is detected after spreading beyond the pancreas, with 2 of 23 systemic metastases occurring in >50% of patients at the time of diagnosis and only 20% of patients meeting the criteria for surgery . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.